智通财经APP获悉，12月31日，恒生指数公司发表《2025年终市场总结报告》。2025年，以恒生指数(恒指)为代表的香港股票市场上升27.8%，为2017年以 来最佳表现。2024年录得17.7%升幅后，除3月底因贸易冲突而有所回落，恒指于2025年大部分时间均稳步向上。2025年升势由多个主要因素组成，包括港 股通创纪录的资金流入、对人工智能未来发展的憧憬，以及降息等。2025年，恒指表现跑赢另外两项旗舰指数—恒生中国企业指数(国指)及恒生科技指数(科 指)，两者分别上涨22.3%及23.5%。值得留意的是，追踪恒生生物科技指数的期货于11月推出，而该指数于2025年上升64.5%。 ESG指数方面，恒生气候变化1.5℃目标指数表现较佳，年度升幅为31.2%。 2025年，恒生综合指数(恒生综指)上涨31.0%。在恒生综指中，中型股上升31.6%，领先大型股(+30.8%)及小型股(+28.8%)。在恒生综指的行业指数中，原材 料业表现最佳，上升161.3%，公用事业则是表现最差的行业，录得5.7%升幅。 香港上市的主题指数方面，恒生港股通创新药指数及恒生医疗保健指数表现最佳，年度升幅分别为64.0%及5 ...

Group 1 - The Hang Seng Index Company announced adjustments to the calculation methods of several indices, including the Hang Seng Hong Kong Stock Connect Innovative Drug Index, Hang Seng Innovative Drug Index, Hang Seng Biotechnology Index, and Hang Seng Hong Kong-US Biotechnology Index [1] - The adjustments aim to enhance the focus on pure innovative drug companies by excluding companies primarily engaged in the CXO industry, which includes Contract Research Organizations (CRO), Contract Manufacturing Organizations (CMO), and Contract Development and Manufacturing Organizations (CDMO) [2][4] - The changes will result in a more concentrated index composition, with the top five constituents of the Hang Seng Hong Kong Stock Connect Innovative Drug Index shifting to companies like Innovent Biologics, BeiGene, and others, while the previous weight of excluded companies was approximately 18.1% [3] Group 2 - The Hang Seng Biotechnology Index will see a reduction in the number of constituents from 50 to a fixed number of 30, along with new trading qualification requirements under the Stock Connect program [6] - The Hang Seng Hong Kong-US Biotechnology Index will also reduce its constituent count from 60 to a fixed number of 40, indicating a significant decrease in the number of stocks included [9] - The adjustments to the indices will take effect on June 30, 2025, with the changes in constituent stocks implemented on September 8, 2025 [9]

Group 1 - The Hang Seng Biotechnology Index will undergo updates in its calculation methodology, including new requirements for the Stock Connect trading eligibility and modifications to the selection criteria [1] - The number of constituent stocks in the Hang Seng Biotechnology Index will be fixed at 30 [1] - The listing history requirement will be removed, and a rapid inclusion mechanism will be introduced [1] Group 2 - The Hang Seng Hong Kong-US Biotechnology Index will also see updates, with the number of constituent stocks fixed at 40 [1]